Previous 10 | Next 10 |
MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of ...
MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President a...
First-in-human data shared at The Liver Meeting ® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH), a disease with no approved therapies, as its lead indication for INT-7...
Intercept Pharmaceuticals ( NASDAQ: ICPT ) announced Monday additional data from its pivotal Phase 3 study for obeticholic acid (OCA) designed to target patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). A previous readout from the trial named REGENERATE in...
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6 MORRISTOWN, N.J., Nov. 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceut...
Summary The 16.4% sales growth of Ocaliva (obeticholic acid or OCA) over the prior year quarter helped lift shares 13.4%. Presentations next week at The Liver Meeting will give a first clinical look at INT-787. More critical is new data from the REGENERATE trial in order to su...
Summary OCALIVA, Intercept's FDA approved therapy, reported nice sales and growth for Q3, 2022; its longer term prospects are clouded. Intercept's lead therapy in development, OCALIVA, is close to resubmitting an sNDA in treatment of NASH; this will be rough sledding. Although...
Intercept Pharmaceuticals, Inc. (ICPT) Q3 2022 Earnings Conference Call November 01, 2022, 08:30 ET Company Participants Nareg Sagherian - Executive Director, Global IR Jerome Durso - President, CEO & Director Linda Richardson - EVP & Chief Commercial Off...
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) were soaring 15.7% higher as of 12:02 p.m. ET on Tuesday. The big gain came after the drugmaker announced its third-quarter results before the market opened. Intercept reported Q3 revenue of $77.6 million, up 16.5% year over yea...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...